ATE369126T1 - Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung - Google Patents

Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung

Info

Publication number
ATE369126T1
ATE369126T1 AT00939884T AT00939884T ATE369126T1 AT E369126 T1 ATE369126 T1 AT E369126T1 AT 00939884 T AT00939884 T AT 00939884T AT 00939884 T AT00939884 T AT 00939884T AT E369126 T1 ATE369126 T1 AT E369126T1
Authority
AT
Austria
Prior art keywords
combination therapy
weight reduction
obesity treatment
phentermine
weight loss
Prior art date
Application number
AT00939884T
Other languages
English (en)
Inventor
Thomas Najarian
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Application granted granted Critical
Publication of ATE369126T1 publication Critical patent/ATE369126T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT00939884T 1999-06-14 2000-06-14 Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung ATE369126T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13902299P 1999-06-14 1999-06-14
US17856300P 2000-01-26 2000-01-26
US18126500P 2000-02-09 2000-02-09

Publications (1)

Publication Number Publication Date
ATE369126T1 true ATE369126T1 (de) 2007-08-15

Family

ID=27385274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939884T ATE369126T1 (de) 1999-06-14 2000-06-14 Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung

Country Status (10)

Country Link
EP (5) EP2305227B1 (de)
AT (1) ATE369126T1 (de)
AU (1) AU770068B2 (de)
CA (2) CA2377330C (de)
CY (1) CY1106974T1 (de)
DE (1) DE60035870T2 (de)
DK (1) DK1187603T3 (de)
ES (4) ES2542868T3 (de)
PT (1) PT1187603E (de)
WO (1) WO2000076493A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
ES2260261T3 (es) 2000-07-07 2006-11-01 Ortho-Mcneil Pharmaceutical, Inc. Derivados anticonvulsivos utiles para la prevencion del desarrollo de diabetes mellitus tipo ii y del sindrome x.
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
JP2004518718A (ja) * 2000-10-30 2004-06-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗糖尿病薬および抗痙攣薬を含んで成る併用療法
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
EP1505967B1 (de) 2002-05-17 2016-07-13 Duke University Verfahren zur behandlung von adipositas
JP2006511543A (ja) * 2002-12-13 2006-04-06 シラグ・アクチエンゲゼルシヤフト 安定なトピラメート製剤
DK1617832T3 (da) 2003-04-29 2008-07-07 Orexigen Therapeutics Inc Præparater til påvirkning af vægttab
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005070461A2 (en) * 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
EP1951212A2 (de) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Zusammensetzungen und verfahren zur erhöhung der insulinsensitivität
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7780730B2 (en) 2006-09-25 2010-08-24 Iyad Saidi Nasal implant introduced through a non-surgical injection technique
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
KR20190042766A (ko) * 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
EP2303025A4 (de) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Verfahren zur behandlung von eingeweidefettbeschwerden
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
EP2340246A2 (de) 2008-06-23 2011-07-06 Janssen Pharmaceutica, N.V. Kristalline form von (2s)-(-)-n-(6-chlor-2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl)sulfamid
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010059586A1 (en) 2008-11-19 2010-05-27 Entrigue Surgical, Inc. Apparatus and methods for correcting nasal valve collapse
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
WO2013028909A1 (en) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Combination therapy for the treatment of sleep-related breathing disorders
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US9480594B2 (en) 2013-02-27 2016-11-01 Spirox, Inc. Nasal implants and systems and methods of use
WO2014134477A1 (en) * 2013-02-28 2014-09-04 Livelight Llc Methods and systems for treating overweight individuals
BR112016011747B1 (pt) 2013-12-05 2020-11-24 Givaudan Sa Uso de um composto modificador de sabor, composiçao comestivel contendo o referido composto bem como metodo para conferir, intensificar ou modificar um sabor umami e/ou salgado em um produto comestivel
CA2958213A1 (en) 2014-08-26 2016-03-03 Spirox, Inc. Nasal implants and systems and method of use
KR20180059863A (ko) 2015-09-25 2018-06-05 스파이록스 인코포레이티드 코 임플란트들 및 시스템들 및 사용 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
EP1187603A1 (de) 2002-03-20
DE60035870T2 (de) 2008-05-08
DK1187603T3 (da) 2007-12-17
EP1187603B1 (de) 2007-08-08
CA2377330A1 (en) 2000-12-21
WO2000076493A1 (en) 2000-12-21
EP2305227A1 (de) 2011-04-06
EP2305226B1 (de) 2015-05-06
EP2305227B1 (de) 2015-05-06
PT1187603E (pt) 2007-11-16
AU770068B2 (en) 2004-02-12
EP1187603A4 (de) 2004-02-11
EP2305226A1 (de) 2011-04-06
EP2305228B1 (de) 2015-05-06
CA2686633A1 (en) 2000-12-21
ES2291215T3 (es) 2008-03-01
CY1106974T1 (el) 2012-09-26
EP2308481B1 (de) 2015-05-06
ES2542891T3 (es) 2015-08-12
EP2308481A1 (de) 2011-04-13
ES2542868T3 (es) 2015-08-12
EP2305228A1 (de) 2011-04-06
CA2377330C (en) 2009-11-24
AU5489600A (en) 2001-01-02
DE60035870D1 (de) 2007-09-20
ES2542892T3 (es) 2015-08-12

Similar Documents

Publication Publication Date Title
ATE369126T1 (de) Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
HUP0301729A2 (hu) Gyógyszer szívelégtelenség megelżzésére és kezelésére
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
EP0824917A3 (de) Verwendung eines Serotonin 5-HT1F Agonists zur Herstellung eines Wirkstoffs für die Behandlung oder die Verbesserung des Schnupfens oder der allergischen Rhinitis
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BRPI0408491A (pt) tratamento da doença de alzheimer
HK1081862A1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
DE69303305T2 (de) Mittel zur Behandlung chronischer Ermüdungserscheinungen
EP1825851A3 (de) Kombinationstherapie zur Gewichtsreduzierung und Fettleibigkeitsbehandlung
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187603

Country of ref document: EP